Victory Capital Management Inc. Buys 38,002 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Victory Capital Management Inc. increased its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 52.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 109,948 shares of the biotechnology company’s stock after purchasing an additional 38,002 shares during the quarter. Victory Capital Management Inc.’s holdings in ADMA Biologics were worth $1,886,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. boosted its holdings in shares of ADMA Biologics by 85.8% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 94,938 shares of the biotechnology company’s stock valued at $1,898,000 after buying an additional 43,836 shares in the last quarter. Natixis Advisors LLC acquired a new stake in ADMA Biologics in the third quarter valued at approximately $345,000. Mutual of America Capital Management LLC purchased a new position in ADMA Biologics in the third quarter worth $701,000. Thrivent Financial for Lutherans purchased a new position in ADMA Biologics in the third quarter worth $3,802,000. Finally, First Turn Management LLC acquired a new position in shares of ADMA Biologics during the third quarter worth $13,293,000. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Trading Up 1.3 %

Shares of ADMA Biologics stock opened at $18.67 on Tuesday. The firm’s 50 day simple moving average is $16.66 and its two-hundred day simple moving average is $17.97. The firm has a market capitalization of $4.41 billion, a price-to-earnings ratio of 66.68 and a beta of 0.60. ADMA Biologics, Inc. has a 12-month low of $5.88 and a 12-month high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.